ReviewAustralian prescriber2022
The anticholinergic burden: from research to practice.
Review in Australian prescriber, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Hospitalisation as an Opportunity to Optimise Quality Use of Medicines in Older Adults: A Systematic Review.Drugs & aging · 2026Pooled it
- Anticholinergic Medication Burden Scales: A Systematic Review.Journal of the American Geriatrics Society · 2026Pooled it
- Effects of premedication with atropine, penehyclidine, and glycopyrrolate on postoperative delirium in older patients undergoing endoscopic gastric or esophageal submucosal dissection: a randomized, double-blind, multicenter, controlled clinical trial.Frontiers in pharmacology · 2026Trial
- Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease.Basic & clinical pharmacology & toxicology · 2026Article
- Comparative predictive performance of anticholinergic burden scales for anticholinergic-related hospitalisation and emergency department visits in older adults: a population-based study of model development and temporal validation.International journal of clinical pharmacy · 2026Article
- Anticholinergic Burden in Individuals with Down Syndrome: An Examination of Risk and Clinical Implications.Journal of personalized medicine · 2026Article
- The quantitative impact of metabolism-inhibiting drugs on the occurrence of adverse drug reactions-A backward selection approach.British journal of clinical pharmacology · 2026Article
- Effects of Nonpharmacological and Nonsurgical Intervention for Lower Urinary Tract Symptoms in Parkinson's Disease: A Systematic Review and Meta-analysis.European urology open science · 2026Review
- Polypharmacy and anticholinergic burden are common but not independently associated with outcomes after emergency laparotomy in older adults.Langenbeck's archives of surgery · 2026Observational
- Comparative Pharmacological Profiling of Psychotherapeutic Drugs Reveals a Functional Taxonomy Based on Direct Inhibition of Smooth Muscle Excitability.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Does the Addition of Vaginal Oestrogen to Anticholinergic Medication Improve Overactive Bladder Symptoms? A Systematic Review and Meta-Analysis.International urogynecology journal · 2026Review
- Lessons from the STOPPCog criteria: prevalence of potentially inappropriate medications for cognition and their association with a cognitive status - a cross-sectional study.Frontiers in pharmacology · 2026Article
- Anticholinergic burden and bone health in rheumatoid arthritis.Revista da Associacao Medica Brasileira (1992) · 2026Article
- A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.Drug, healthcare and patient safety · 2026Review
- Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions.Pharmacy (Basel, Switzerland) · 2025Article
- Association Between Sugammadex Use and Risk of Postoperative Urinary Complications after Metabolic and Bariatric Surgery: A Multi-Institutional Study.Obesity surgery · 2025Article
- Article
- Anticholinergic and Sedative Medication Burden in Croatian Older Adults: EuroAgeism Cohort Findings.Pharmacy (Basel, Switzerland) · 2025Article
- Retrospective multi-centre cohort study of polypharmacy, the Drug Burden Index and associations with outcomes in older surgical inpatients.Age and ageing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs with anticholinergic effects are known to cause adverse effects such as dry mouth, constipation and urinary retention. In older people drugs with anticholinergic effects may contribute to cognitive decline and a loss of functional capacity. Many drugs that are not in the anticholinergic drug class also have anticholinergic effects. They include antidepressants, antipsychotics and antihistamines. Taking multiple drugs with anticholinergic effects creates an anticholinergic burden. It is important that clinicians identify which patients are at risk. There are several tools to assess the anticholinergic burden. Clinicians can use these tools to make a pharmacological risk assessment when reviewing a patient's medicines. This can assist decisions about continuing or stopping drugs with anticholinergic effects. Deprescribing drugs with anticholinergic effects has several potential benefits in older people. In addition to reversing adverse effects, deprescribing may prevent problems such as falls.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.